GAAP loss but stronger Q4 for Quaker Houghton (NYSE: KWR) in 2025
Quaker Houghton reported higher fourth-quarter 2025 results, with net sales of $468.5 million, up 6% year over year. GAAP net income rose to $20.7 million, or $1.18 per diluted share, while non-GAAP earnings were $28.9 million, or $1.65 per share.
For full-year 2025, net sales reached $1.89 billion, but the company posted a GAAP net loss of $2.5 million, or $0.14 per share, driven by an $88.8 million impairment and $35.1 million of restructuring charges. Non-GAAP net income was $123.2 million, or $7.02 per share, and adjusted EBITDA was $299.2 million. Quaker Houghton generated $136.5 million of operating cash flow, ended the year with $691.4 million of net debt and a 2.3x leverage ratio, and returned $75.9 million to shareholders through dividends and share repurchases.
Positive
- Fourth-quarter 2025 adjusted EBITDA rose 11% year over year to $71.9 million, with non-GAAP EPS up 24% to $1.65, showing improving profitability despite soft end markets.
- The company generated strong 2025 operating cash flow of $136.5 million and kept leverage moderate at 2.3x net debt to trailing adjusted EBITDA while still funding acquisitions and shareholder returns.
Negative
- Full-year 2025 swung to a GAAP net loss of $2.5 million from $116.6 million net income in 2024, mainly due to an $88.8 million impairment and $35.1 million of restructuring charges.
- Adjusted EBITDA for 2025 declined to $299.2 million from $310.9 million and non-GAAP EPS fell to $7.02 from $7.44, indicating some margin and earnings pressure versus the prior year.
Insights
Solid Q4 and cash generation offset a GAAP loss driven by large non-cash charges.
Quaker Houghton delivered Q4 2025 net sales of $468.5 million, up 6% year over year, with adjusted EBITDA of $71.9 million, an 11% increase. Non-GAAP EPS rose 24% to $1.65, reflecting contributions from acquisitions and better operating margins.
For 2025 overall, revenue grew to $1.89 billion, but an $88.8 million impairment and $35.1 million of restructuring turned prior-year net income of $116.6 million into a small GAAP loss. Non-GAAP net income of $123.2 million and adjusted EBITDA of $299.2 million show underlying profitability remained healthy, though margins softened versus 2024.
Balance sheet leverage was manageable at 2.3x net debt to trailing adjusted EBITDA, with $136.5 million of operating cash flow funding $41.5 million of share repurchases and ongoing acquisitions. Management highlighted soft end markets but pointed to new business wins and expects revenue and adjusted EBITDA growth in 2026, subject to macro and sector conditions.
8-K Event Classification
FAQ
How did Quaker Houghton (KWR) perform in Q4 2025?
What were Quaker Houghton’s full-year 2025 results?
Why did Quaker Houghton report a GAAP net loss in 2025?
How strong was Quaker Houghton’s cash flow and leverage in 2025?
What shareholder returns did Quaker Houghton (KWR) provide in 2025?
How did Quaker Houghton’s regional segments perform in Q4 2025?
What non-GAAP measures does Quaker Houghton emphasize for 2025?
AI-generated analysis. How Rhea-AI works. Not financial advice.
| (State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) | ||||
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
| Exhibit No. | Description | |||||||
99.1 | Press Release of Quaker Chemical Corporation dated February 23, 2026 (furnished herewith). | |||||||
99.2 | Supplemental Information related to the fourth quarter and full year ended December 31, 2025 (furnished herewith). | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
| QUAKER CHEMICAL CORPORATION | ||||||||
Date: February 23, 2026 | By: | /s/ Thomas Coler | ||||||
| Thomas Coler | ||||||||
| Executive Vice President, Chief Financial Officer | ||||||||
NEWS Contact: John Dalhoff Investor Relations investor@quakerhoughton.com T. 1.610.684.7822 | ||||||||

For Release: Immediate | ||||||||
Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||||||||||
($ in thousands, except per share data) | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||
Net sales | $ | 468,478 | $ | 444,086 | $ | 1,888,634 | $ | 1,839,686 | |||||||||||||||
Net income (loss) attributable to Quaker Chemical Corporation | 20,701 | 14,186 | (2,488) | 116,644 | |||||||||||||||||||
Net income (loss) attributable to Quaker Chemical Corporation common shareholders – diluted | 1.18 | 0.81 | (0.14) | 6.51 | |||||||||||||||||||
Non-GAAP net income * | 28,857 | 23,570 | 123,155 | 133,456 | |||||||||||||||||||
Non-GAAP earnings per diluted share * | 1.65 | 1.33 | 7.02 | 7.44 | |||||||||||||||||||
Adjusted EBITDA * | 71,861 | 64,783 | 299,238 | 310,918 | |||||||||||||||||||
Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
Net Sales * | |||||||||||||||||||||||
Americas | $ | 207,772 | $ | 208,585 | $ | 865,332 | $ | 882,131 | |||||||||||||||
EMEA | 135,009 | 125,877 | 548,110 | 536,435 | |||||||||||||||||||
Asia/Pacific | 125,697 | 109,624 | 475,192 | 421,120 | |||||||||||||||||||
Total net sales | $ | 468,478 | $ | 444,086 | $ | 1,888,634 | $ | 1,839,686 | |||||||||||||||
Segment operating earnings * | |||||||||||||||||||||||
Americas | $ | 51,218 | $ | 50,930 | $ | 227,569 | $ | 243,957 | |||||||||||||||
EMEA | 21,773 | 18,559 | 96,640 | 99,426 | |||||||||||||||||||
Asia/Pacific | 34,009 | 30,705 | 124,223 | 122,738 | |||||||||||||||||||
Total segment operating earnings | $ | 107,000 | $ | 100,194 | $ | 448,432 | $ | 466,121 | |||||||||||||||
Sales volumes | Selling price & product mix | Foreign currency | Acquisition & other | Total | ||||||||||||||||||||||||||||
Americas | (4) | % | — | % | 2 | % | 2 | % | — | % | ||||||||||||||||||||||
EMEA | (2) | % | 2 | % | 4 | % | 3 | % | 7 | % | ||||||||||||||||||||||
Asia/Pacific | 4 | % | (4) | % | — | % | 15 | % | 15 | % | ||||||||||||||||||||||
Consolidated | (1) | % | (1) | % | 2 | % | 6 | % | 6 | % | ||||||||||||||||||||||
Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||||||||||
Non-GAAP Gross Profit and Margin Reconciliations | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||
Gross profit | $ | 165,524 | $ | 156,200 | $ | 679,372 | $ | 686,030 | |||||||||||||||
Acquisition-related step-up inventory amortization | — | — | 6,022 | — | |||||||||||||||||||
Gain on inventory and other adjustments | — | — | (2,933) | — | |||||||||||||||||||
Non-GAAP gross profit | $ | 165,524 | $ | 156,200 | $ | 682,461 | $ | 686,030 | |||||||||||||||
Non-GAAP gross margin (%) | 35.3 | % | 35.2 | % | 36.1 | % | 37.3 | % | |||||||||||||||
Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||||||||||
Non-GAAP Operating Income and Margin Reconciliations | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||
Operating income | $ | 31,231 | $ | 29,013 | $ | 52,986 | $ | 194,706 | |||||||||||||||
Acquisition-related step-up inventory amortization | — | — | 6,022 | — | |||||||||||||||||||
Restructuring and related charges, net | 4,002 | 1,743 | 35,130 | 6,530 | |||||||||||||||||||
Acquisition-related expenses | 7,256 | 956 | 12,031 | 1,854 | |||||||||||||||||||
Strategic planning expenses (credits) | 7 | — | 579 | (290) | |||||||||||||||||||
Executive transition costs | — | 6,556 | — | 7,288 | |||||||||||||||||||
Customer insolvency costs | — | 1,691 | — | 3,213 | |||||||||||||||||||
Gain on inventory and other adjustments | — | — | (3,256) | — | |||||||||||||||||||
Impairment charges | — | — | 88,840 | — | |||||||||||||||||||
Acquisition-related depreciation and amortization | 1,638 | — | 4,975 | — | |||||||||||||||||||
Other charges | 975 | 494 | 2,098 | 399 | |||||||||||||||||||
Non-GAAP operating income | $ | 45,109 | $ | 40,453 | $ | 199,405 | $ | 213,700 | |||||||||||||||
Non-GAAP operating margin (%) | 9.6 | % | 9.1 | % | 10.6 | % | 11.6 | % | |||||||||||||||
EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin and Non-GAAP Net Income Reconciliations | Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
Net income attributable to Quaker Chemical Corporation | $ | 20,701 | $ | 14,186 | $ | (2,488) | $ | 116,644 | |||||||||||||||
Depreciation and amortization (a) | 25,215 | 21,201 | 94,402 | 85,108 | |||||||||||||||||||
Interest expense | 10,783 | 9,077 | 44,048 | 41,002 | |||||||||||||||||||
Taxes on income before equity in net income of associated companies (b) | 2,327 | 8,847 | 24,607 | 49,300 | |||||||||||||||||||
EBITDA | 59,026 | 53,311 | 160,569 | 292,054 | |||||||||||||||||||
Equity loss (income) in a captive insurance company | 165 | (1,664) | (4,272) | (2,930) | |||||||||||||||||||
Acquisition-related step-up inventory amortization | — | — | 6,022 | — | |||||||||||||||||||
Restructuring and related charges, net | 4,002 | 1,743 | 35,130 | 6,530 | |||||||||||||||||||
Acquisition-related expenses | 7,256 | 956 | 12,031 | 1,454 | |||||||||||||||||||
Strategic planning expenses (credits) | 7 | — | 579 | (290) | |||||||||||||||||||
Gain on inventory and other adjustments | — | — | (3,256) | — | |||||||||||||||||||
Pension and postretirement benefit costs, non-service components | 325 | 445 | 1,676 | 1,827 | |||||||||||||||||||
Executive transition costs | — | 6,556 | — | 7,288 | |||||||||||||||||||
Customer insolvency costs | — | 1,691 | — | 3,213 | |||||||||||||||||||
Currency conversion impacts of hyper-inflationary economies | 143 | 478 | 2,216 | 811 | |||||||||||||||||||
Impairment charges | — | — | 88,840 | — | |||||||||||||||||||
Loss on acquisition-related hedges | — | — | 1,351 | — | |||||||||||||||||||
Loss (gain) on sale of assets | — | 28 | (2,534) | (492) | |||||||||||||||||||
Multiemployer plan withdrawal charge | — | — | 923 | — | |||||||||||||||||||
Brazilian non-income tax credits | — | — | (1,762) | — | |||||||||||||||||||
Other charges | 937 | 1,239 | 1,725 | 1,453 | |||||||||||||||||||
Adjusted EBITDA | $ | 71,861 | $ | 64,783 | $ | 299,238 | $ | 310,918 | |||||||||||||||
Adjusted EBITDA margin (%) | 15.3 | % | 14.6 | % | 15.8 | % | 16.9 | % | |||||||||||||||
Adjusted EBITDA | $ | 71,861 | $ | 64,783 | $ | 299,238 | $ | 310,918 | |||||||||||||||
Less: Depreciation and amortization (a) | 25,215 | 21,201 | 94,402 | 85,108 | |||||||||||||||||||
Less: Interest expense | 10,783 | 9,077 | 44,048 | 41,002 | |||||||||||||||||||
Less: Taxes on income before equity in net income of associated companies - adjusted (b) | 8,644 | 10,935 | 42,608 | 51,352 | |||||||||||||||||||
Plus: Acquisition-related depreciation and amortization | 1,638 | — | 4,975 | — | |||||||||||||||||||
Non-GAAP net income | $ | 28,857 | $ | 23,570 | $ | 123,155 | $ | 133,456 | |||||||||||||||
Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||||||||||
Non-GAAP Earnings per Diluted Share Reconciliations: | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||
GAAP earnings per diluted share attributable to Quaker Chemical Corporation common shareholders | $ | 1.18 | $ | 0.81 | $ | (0.14) | $ | 6.51 | |||||||||||||||
Equity loss (income) in a captive insurance company | 0.01 | (0.09) | (0.24) | (0.16) | |||||||||||||||||||
Acquisition-related step-up inventory amortization | — | — | 0.25 | — | |||||||||||||||||||
Restructuring and related charges, net | 0.18 | 0.08 | 1.49 | 0.28 | |||||||||||||||||||
Acquisition-related expenses | 0.32 | 0.04 | 0.53 | 0.06 | |||||||||||||||||||
Strategic planning expenses (credits) | — | — | 0.03 | (0.01) | |||||||||||||||||||
Pension and postretirement benefit costs, non-service components | 0.01 | 0.01 | 0.07 | 0.05 | |||||||||||||||||||
Executive transition costs | — | 0.28 | — | 0.31 | |||||||||||||||||||
Customer insolvency costs | — | 0.07 | — | 0.13 | |||||||||||||||||||
Currency conversion impacts of hyper-inflationary economies | 0.01 | 0.03 | 0.13 | 0.05 | |||||||||||||||||||
Impairment charges | — | — | 4.91 | — | |||||||||||||||||||
Acquisition-related depreciation and amortization | 0.07 | — | 0.20 | — | |||||||||||||||||||
Loss on acquisition-related hedges | — | — | 0.06 | — | |||||||||||||||||||
Loss (gain) on sale of assets | — | — | (0.11) | (0.02) | |||||||||||||||||||
Multiemployer plan withdrawal charge | — | — | 0.04 | — | |||||||||||||||||||
Brazilian non-income tax credits | — | — | (0.08) | — | |||||||||||||||||||
Gain on inventory and other adjustments | — | — | (0.14) | — | |||||||||||||||||||
Other charges | 0.04 | 0.04 | 0.08 | 0.07 | |||||||||||||||||||
Impact of certain discrete tax items (c) | (0.17) | 0.06 | (0.06) | 0.17 | |||||||||||||||||||
Non-GAAP earnings per diluted share | $ | 1.65 | $ | 1.33 | $ | 7.02 | $ | 7.44 | |||||||||||||||
Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
Net Sales | |||||||||||||||||||||||
Americas | $ | 207,772 | $ | 208,585 | $ | 865,332 | $ | 882,131 | |||||||||||||||
EMEA | 135,009 | 125,877 | 548,110 | 536,435 | |||||||||||||||||||
Asia/Pacific | 125,697 | 109,624 | 475,192 | 421,120 | |||||||||||||||||||
Total net sales | $ | 468,478 | $ | 444,086 | $ | 1,888,634 | $ | 1,839,686 | |||||||||||||||
Segment operating earnings | |||||||||||||||||||||||
Americas | $ | 51,218 | $ | 50,930 | $ | 227,569 | $ | 243,957 | |||||||||||||||
EMEA | 21,773 | 18,559 | 96,640 | 99,426 | |||||||||||||||||||
Asia/Pacific | 34,009 | 30,705 | 124,223 | 122,738 | |||||||||||||||||||
Total segment operating earnings | 107,000 | 100,194 | 448,432 | 466,121 | |||||||||||||||||||
Restructuring and related charges, net | (4,002) | (1,743) | (35,130) | (6,530) | |||||||||||||||||||
Impairment charges | — | — | (88,840) | — | |||||||||||||||||||
Non-operating and administrative expenses | (54,514) | (54,418) | (205,651) | (203,956) | |||||||||||||||||||
Depreciation of corporate assets and amortization | (17,253) | (15,020) | (65,825) | (60,929) | |||||||||||||||||||
Operating income | 31,231 | 29,013 | 52,986 | 194,706 | |||||||||||||||||||
Other (expense) income, net | (277) | (931) | (1,909) | 1,354 | |||||||||||||||||||
Interest expense, net | (10,783) | (9,077) | (44,048) | (41,002) | |||||||||||||||||||
Income before taxes and equity in net income of associated companies | $ | 20,171 | $ | 19,005 | $ | 7,029 | $ | 155,058 | |||||||||||||||
Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
Net sales | $ | 468,478 | $ | 444,086 | $ | 1,888,634 | $ | 1,839,686 | |||||||||||||||
Cost of goods sold | 302,954 | 287,886 | 1,209,262 | 1,153,656 | |||||||||||||||||||
Gross profit | 165,524 | 156,200 | 679,372 | 686,030 | |||||||||||||||||||
Selling, general and administrative expenses | 130,291 | 125,444 | 502,416 | 484,794 | |||||||||||||||||||
Impairment charges | — | — | 88,840 | — | |||||||||||||||||||
Restructuring and related charges, net | 4,002 | 1,743 | 35,130 | 6,530 | |||||||||||||||||||
Operating income | 31,231 | 29,013 | 52,986 | 194,706 | |||||||||||||||||||
Other (expense) income, net | (277) | (931) | (1,909) | 1,354 | |||||||||||||||||||
Interest expense, net | (10,783) | (9,077) | (44,048) | (41,002) | |||||||||||||||||||
Income before taxes and equity in net income of associated companies | 20,171 | 19,005 | 7,029 | 155,058 | |||||||||||||||||||
Taxes on income before equity in net income of associated companies | 2,327 | 8,847 | 24,607 | 49,300 | |||||||||||||||||||
Income (loss) before equity in net income of associated companies | 17,844 | 10,158 | (17,578) | 105,758 | |||||||||||||||||||
Equity in net income of associated companies | 2,915 | 4,031 | 15,177 | 10,971 | |||||||||||||||||||
Net income (loss) | 20,759 | 14,189 | (2,401) | 116,729 | |||||||||||||||||||
Less: Net income attributable to noncontrolling interest | 58 | 3 | 87 | 85 | |||||||||||||||||||
Net income (loss) attributable to Quaker Chemical Corporation | $ | 20,701 | $ | 14,186 | $ | (2,488) | $ | 116,644 | |||||||||||||||
Per share data: | |||||||||||||||||||||||
Net income (loss) attributable to Quaker Chemical Corporation common shareholders – basic | $ | 1.18 | $ | 0.80 | $ | (0.14) | $ | 6.51 | |||||||||||||||
Net income (loss) attributable to Quaker Chemical Corporation common shareholders – diluted | $ | 1.18 | $ | 0.81 | $ | (0.14) | $ | 6.51 | |||||||||||||||
Basic weighted average common shares outstanding | 17,320,177 | 17,735,186 | 17,472,907 | 17,850,462 | |||||||||||||||||||
Diluted weighted average common shares outstanding | 17,433,193 | 17,765,771 | 17,472,907 | 17,870,067 | |||||||||||||||||||
December 31, | |||||||||||
2025 | 2024 | ||||||||||
ASSETS | |||||||||||
Current assets | |||||||||||
Cash and cash equivalents | $ | 179,829 | $ | 188,880 | |||||||
Accounts receivable, net | 417,157 | 400,126 | |||||||||
Inventories | 265,776 | 227,472 | |||||||||
Prepaid expenses and other current assets | 58,428 | 59,939 | |||||||||
Total current assets | 921,190 | 876,417 | |||||||||
Property, plant and equipment, net | 313,423 | 229,532 | |||||||||
Right-of-use lease assets | 38,737 | 34,120 | |||||||||
Goodwill | 501,720 | 518,894 | |||||||||
Other intangible assets, net | 873,540 | 827,098 | |||||||||
Investments in associated companies | 106,915 | 98,012 | |||||||||
Deferred tax assets | 12,128 | 9,216 | |||||||||
Other non-current assets | 30,283 | 17,360 | |||||||||
Total assets | $ | 2,797,936 | $ | 2,610,649 | |||||||
LIABILITIES AND EQUITY | |||||||||||
Current liabilities | |||||||||||
Short-term borrowings and current portion of long-term debt | $ | 35,657 | $ | 37,554 | |||||||
Accounts payable | 198,929 | 198,137 | |||||||||
Dividends payable | 8,804 | 8,572 | |||||||||
Accrued compensation | 41,192 | 50,212 | |||||||||
Accrued restructuring | 8,351 | 2,297 | |||||||||
Accrued pension and postretirement benefits | 2,126 | 2,328 | |||||||||
Other accrued liabilities | 85,097 | 80,668 | |||||||||
Total current liabilities | 380,156 | 379,768 | |||||||||
Long-term debt | 834,901 | 669,614 | |||||||||
Long-term lease liabilities | 22,759 | 20,028 | |||||||||
Deferred tax liabilities | 140,814 | 138,828 | |||||||||
Non-current accrued pension and postretirement benefits | 20,615 | 23,783 | |||||||||
Other non-current liabilities | 22,192 | 24,445 | |||||||||
Total liabilities | 1,421,437 | 1,256,466 | |||||||||
Equity | |||||||||||
Common stock, $1 par value; authorized 30,000,000 shares; issued and outstanding 2025 – 17,331,779 shares; 2024 – 17,673,607 shares | 17,332 | 17,674 | |||||||||
Capital in excess of par value | 874,826 | 903,781 | |||||||||
Retained earnings | 596,616 | 633,731 | |||||||||
Accumulated other comprehensive loss | (115,661) | (201,619) | |||||||||
Total Quaker shareholders’ equity | 1,373,113 | 1,353,567 | |||||||||
Noncontrolling interest | 3,386 | 616 | |||||||||
Total equity | 1,376,499 | 1,354,183 | |||||||||
Total liabilities and equity | $ | 2,797,936 | $ | 2,610,649 | |||||||
Year Ended December 31, | |||||||||||
2025 | 2024 | ||||||||||
Cash flows from operating activities | |||||||||||
Net (loss) income | $ | (2,401) | $ | 116,729 | |||||||
Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
Depreciation and amortization | 93,453 | 84,119 | |||||||||
Equity in undistributed earnings of associated companies, net of dividends | (6,648) | (2,733) | |||||||||
Deferred income taxes | (30,428) | (10,033) | |||||||||
Restructuring and related charges | 35,130 | 6,530 | |||||||||
Share-based compensation | 13,611 | 14,991 | |||||||||
Gain on disposal of property, plant, equipment and other assets | (2,204) | (810) | |||||||||
Inventory step-up amortization | 6,022 | — | |||||||||
Impairment charges | 88,840 | — | |||||||||
Uncertain tax positions (non-deferred portion) | (5,708) | (2,372) | |||||||||
Pension and other postretirement benefits | (4,132) | (4,460) | |||||||||
Other adjustments | (5,564) | 6,280 | |||||||||
Increase (decrease) in change in operating assets and liabilities, net of acquisitions | |||||||||||
Accounts receivable | 24,232 | 24,975 | |||||||||
Inventories | (12,239) | (3,244) | |||||||||
Prepaid expenses and other assets | 3,069 | (6,242) | |||||||||
Accrued restructuring | (26,598) | (7,595) | |||||||||
Accounts payable and accrued liabilities | (30,268) | (8,637) | |||||||||
Estimated taxes on loss | (1,714) | (2,920) | |||||||||
Net cash provided by operating activities | 136,453 | 204,578 | |||||||||
Cash flows from investing activities | |||||||||||
Investments in property, plant and equipment | (55,856) | (41,794) | |||||||||
Payments related to acquisitions, net of cash acquired | (164,209) | (39,302) | |||||||||
Proceeds from disposition of assets | 2,995 | 4,676 | |||||||||
Other investing activities | 2,951 | — | |||||||||
Net cash used in investing activities | (214,119) | (76,420) | |||||||||
Cash flows from financing activities | |||||||||||
Payments of long-term debt | (34,722) | (57,221) | |||||||||
Borrowings on revolving credit facilities, net | 174,242 | 17,916 | |||||||||
(Payments) borrowings on other debt, net | (386) | 1,441 | |||||||||
Dividends paid | (34,393) | (33,170) | |||||||||
Shares purchased under share repurchase program | (41,521) | (49,247) | |||||||||
Other stock related activity | (1,387) | (2,383) | |||||||||
Net cash provided by (used in) financing activities | 61,833 | (122,664) | |||||||||
Effect of foreign exchange rate changes on cash | 6,782 | (11,141) | |||||||||
Net decrease in cash and cash equivalents | (9,051) | (5,647) | |||||||||
Cash and cash equivalents at the beginning of the period | 188,880 | 194,527 | |||||||||
Cash and cash equivalents at the end of the period | $ | 179,829 | $ | 188,880 | |||||||